Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:14:56 EDT Sun 12 Oct 2025
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - https://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q5.81.46·1.557.81.49-0.15-9.14,913.77,1165,6821.66  1.66  1.452.175  0.283619:51:55Oct 0815 min RT 2¢

Recent Trades - Last 10 of 5682
Time ETExPriceChangeVolume
19:51:55Q1.54-0.10591
19:51:55Q1.54-0.10109
19:51:55Q1.54-0.10300
19:47:16Q1.55-0.09100
19:45:59Q1.5473-0.09273,000
19:09:19Q1.54-0.101
18:45:55Q1.5027-0.1373100
18:40:29Q1.55-0.091
18:36:10Q1.56-0.08700
18:32:04Q1.5502-0.089810

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-10-08 07:59U:LXRXNews ReleaseLexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
2025-09-22 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista(TM) in Type 1 Diabetes
2025-09-17 07:00U:LXRXNews ReleasePilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
2025-09-11 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
2025-09-08 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista(TM) in Type 1 Diabetes
2025-09-04 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
2025-09-03 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
2025-09-02 08:30U:LXRXNews ReleaseSotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
2025-08-27 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
2025-08-06 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-07-31 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-07-23 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-07-18 08:00U:LXRXNews ReleaseLexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
2025-06-23 08:00U:LXRXNews ReleaseData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-06-18 08:30U:LXRXNews ReleaseLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-05-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-19 08:00U:LXRXNews ReleaseSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
2025-05-13 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-05-06 16:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
2025-05-06 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025